

25th Annual Meeting

Friday, October 21st, 2016

Hyatt Regency Chicago,

151 East Wacker Drive, Chicago, Illinois



International Society For Anaesthetic Pharmacology
2016 Registration Brochure

6737 W. Washington St., Suite 4210 • Milwaukee, WI 53214
(p) 414-755-6296 • (f) 414-276-7704 • www.isaponline.org • isaphq@isaponline.org

25th Annual Meeting Agenda · Chicago, Illinois

7:00 – 8:00	Breakfast
8:00 – 8:10	Welcome ISAP President, Vesna Jevtovic-Todorovic, MD, PhD, MBA
8:10 – 8:15	Introduction to the Program Program Co-Chair Hugo E.M. Vereeke, MD, PhD
8:15 – 9:00	Session 1 – ISAP's 25th Anniversary
8:15 – 8:35	ISAP: A History of a Significant Society! Tom C. Krejcie, MD
8:35 – 9:00	The History (and Future) of Target Controlled Infusion Michel Struys, MD, PhD, FRCA (Hon)
9:00 – 9:30	Break with Exhibitors
9:30 – 11:30	Session 2 – Persistent Postoperative Cognitive Dysfunction/ Decline (POCD) – Myth or Reality?
9:30 – 10:00	Assessing Cognitive Function, Postoperative Cognitive Dysfunction, and the Cognitive Trajectory: Lessons from the International Study of Postoperative Cognitive Dysfunction (ISPOCD) Jacob Steinmetz, MD, PhD
10:00 – 10:30	POCD – A Reality! Terri Monk, MD, MS
10:30 – 11:00	POCD – A Myth! Michael S. Avidan, MBBCh
11:00 – 11:30	Persistent POCD – Panel Discussion on the Presented Evidence Jacob Steinmetz, MD, PhD, Terri Monk, MD, MS and Michael S. Avidan, MBBCh
11:30 – 12:30	Lunch, ISAP Business Meeting, Break with Exhibitors
12:30 – 13:30	Moderated Poster Discussion ISAP Board of Directors
13:30 – 14:30	Session 3 – New Concepts for Drug Titration
13:30 – 14:00	Noxious Stimulation Response Index: The Next Generation of MAC? Laura Hannivoort, MD
14:00 – 14:30	Allometric Scaling in PK-PD Modeling Douglas Eleveld, PhD
14:30 – 15:00	Break with Exhibitors
15:00 – 16:00	Session 4 – Anesthetics and Depression
15:00 – 15:30	The Road to (2R,6R)-Hydroxynorketamine and Beyond: The Development of a New Class of Antidepressant Agents Irving Wainer, PhD, DHC
15:30 – 16:00	Nitrous Oxide as a Treatment for Major Depression Peter Nagele, MD, MSc
16:00 – 16:45	Keynote Speaker & Lifetime Achievement Award Winner: Talmage Egan, MD
16:45 – 17:00	Closing Remarks
17:00 – 18:00	President's Reception

Planning Committee

Hugo E.M. Vereecke, MD, PhD
University Medical Center
Groningen
Groningen, Netherlands

Michael Avram, PhD
Northwestern University
Feinberg School of Medicine
Chicago, IL USA

Faculty

Michael S. Avidan, MBBCh
Washington University School of
Medicine in St. Louis
St. Louis, MO USA

Douglas Eleveld, PhD
University Medical Center
Groningen
Groningen, Netherlands

Talmage Egan, MD
University of Utah
Salt Lake City, UT USA

Laura Hannivoort, MD
University Medical Center
Groningen
Groningen, Netherlands

Vesna Jevtovic-Todorovic,
MD, PhD, MBA
University of Colorado
Denver, CO USA

Tom C. Krejcie, MD
Northwestern University
Feinberg School of Medicine
Chicago, IL USA

Terri Monk, MD, MS
University of Missouri –
Columbia
Columbia, MO USA

Peter Nagele, MD, MSc
Washington University
St. Louis, MO USA

Jacob Steinmetz, MD, PhD
University of Copenhagen
Rigshospitalet, Denmark

Michel Struys, MD, PhD,
FRCA (Hon)
University Medical Center
Groningen
Groningen, Netherlands

Irving Wainer, PhD, DHC
Mitchell Woods Pharmaceuticals
Shelton, CT USA



International Society for Anaesthetic Pharmacology
6737 W Washington St
Suite 4210
Milwaukee, WI 53214

Registration Information Enclosed

25th Annual Meeting

Friday, October 21st, 2016 • Chicago, Illinois



Learning Objectives

The overall purpose of this activity is to enable the learner to:

1. Decide whether he/she needs to adjust anesthetic management to avoid persistent post-operative cognitive decline.
2. Comprehend the potential of new drug modeling technology to improve clinical drug titration.
3. Understand the mechanisms of N₂O and ketamine as modulators of depression.
4. Learn about the history of the International Society of Anesthetic Pharmacology (ISAP) and of the implementation of target controlled infusions (TCI) around the world.

Practice Gaps

- A long term outcome of anesthesia is "persistent post-operative cognitive decline." Anesthesiologists (both clinicians and academics) are in doubt whether they need to adjust their drug titration in view of these outcomes.
- Improving technology for modeling drug-concentration and effect leads to better control of the dose-effect relationship, but is insufficiently known by anesthesiologists.
- The use of nitrous oxide may negatively affect patients that are at risk for depression. Ketamine may play a role in the treatment of depression.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Amedco and the International Society of Anaesthetic Pharmacology (ISAP). Amedco is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Amedco designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.